Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04203160|
Recruitment Status : Recruiting
First Posted : December 18, 2019
Last Update Posted : December 22, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus cisplatin) compared to gemcitabine plus cisplatin alone.
This research study has two parts:
In the phase 1 portion of this study, patients will receive a combination of CPI-613 and standard of care chemotherapy. Dose levels of CPI-613 will be adjusted to find the best dose, which will be the recommended phase 2 dose level.
In the phase 2 portion of this study, patients will be randomized into two arms. Patients in Arm A will receive the combination of the recommended dose level of CPI-613 and standard of care chemotherapy. Patients in Arm B will receive standard of care chemotherapy.
At the end of the study, researchers will compare the health outcomes of the patients that received CPI-613 + standard care to the outcomes of patients that received only standard care.
|Condition or disease||Intervention/treatment||Phase|
|Biliary Tract Cancer||Drug: CPI 613 Drug: Gemcitabine Drug: Cisplatin||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||78 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Phase II: 2:1 Randomization with Bayesian Design Control Arm|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)|
|Actual Study Start Date :||June 23, 2020|
|Estimated Primary Completion Date :||June 2024|
|Estimated Study Completion Date :||June 2025|
Experimental: Phase 1 and Phase 2, Arm A (investigational)
On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.
Drug: CPI 613
Other Name: Devimistat®
Other Name: Gemzar®
Other Name: CDDP, Platinol®, NSC-119875
Active Comparator: Phase 2, Arm B (standard of care)
On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.
Other Name: Gemzar®
Other Name: CDDP, Platinol®, NSC-119875
- Phase 1: Incidence of dose-limiting toxicity [ Time Frame: Up to day 22 ]Dose limiting toxicities will determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of combination therapy with CPI-613 + gemcitabine and cisplatin. Assessed using the NCI CTCAE v5.0
- Phase 2: Overall Response Rate (ORR) [ Time Frame: Until last dose of study treatment (up to 2 years) ]Objective response assessment will be determined by review of CT or MR scans of the chest, abdomen and pelvis. ORR (Partial Response + Complete Response) will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, during active study treatment. All enrolled patients who receive at least 1 cycle of therapy and have their disease re-evaluated will be considered evaluable for response. (Note: Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)
- Median Progression Free Survival (PFS) [ Time Frame: Until last dose of study treatment (up to 2 years) ]PFS will be determined from date of first study treatment until the date of radiological or clinical progression (leading to withdrawal from the study) or date of last disease evaluation (for patients without progression). It will be calculated using the product-limit method of Kaplan and Meier. All patients that receive at least one dose of study treatment will be considered evaluable.
- Median Overall Survival (OS) [ Time Frame: Up to 3 years after enrollment ]From date of first study treatment until date of last disease evaluation or until death from any cause. Using the product-limit method of Kaplan and Meier.
- Incidence of Toxicities [ Time Frame: Up to 100 days after last dose of study treatment ]To evaluate the safety of CPI-613 in combination with gemcitabine and cisplatin in this patient population, assessed using the Common Toxicity Criteria for Adverse Events (CTCAE) v5.0. All patients that receive at least one dose of study treatment will be considered evaluable.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients must have a pathologically or cytologically confirmed carcinoma (except neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or gallbladder) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed cholangiocarcinoma/hepatocellular carcinoma histology are excluded.
- Patients may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC. Prior peri-operative chemotherapy is permitted provided it was completed > 6 months from enrollment.
- Patients may have received prior radiation, chemoembolization, radioembolization or other local ablative therapies or hepatic resection if completed ≥ 4 weeks prior to enrollment AND if patient has recovered to ≤ grade 1 toxicity. Extrahepatic palliative radiation is permitted if completed ≥ 2 weeks prior to enrollment AND if patient has recovered to ≤ grade 1 toxicity
- Patients must have radiographically measurable disease (as per RECISTv1.1) in at least one site not previously treated with radiation or liver directed therapy (including bland, chemo- or radio-embolization, or ablation) either within the liver or in a metastatic site.
- Must be ≥ 18 years of age.
- Must have an ECOG performance status of 0-1.
- Ability to understand and willingness to sign IRB-approved informed consent.
- Willing to provide archived tissue, if available, from a previous diagnostic biopsy or surgery.
- Must be able to tolerate CT and/or MRI with contrast.
- Adequate organ function (per protocol) obtained ≤ 2 weeks prior to enrollment.
- Women of child-bearing potential and men must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation and for 6 months (for men and women) following completion of study therapy.
- Prior history of brain metastasis (unless previously treated, asymptomatic and stable for at least 3 months) or organ transplant.
- Underwent a major surgical procedure < 4 weeks prior to enrollment.
- Active second malignancy other than in situ cancer or localized prostate cancer (Gleason score <8). Patients with history of other malignancy are eligible provided primary treatment of that cancer was completed > 1 year prior to enrollment and the patient is free of clinical or radiologic evidence of recurrent or progressive malignancy.
- Ongoing active, uncontrolled infection (must be afebrile for > 48 hours off antibiotics) .
- Psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements.
- Pregnancy or breastfeeding. (Women must not be pregnant or breastfeeding since study drugs may harm the fetus or child. All females of childbearing potential [not surgically sterilized and between menarche and 1 year post menopause] must have a negative screening pregnancy test.)
- Active heart disease including symptomatic heart failure (NYHA class 3 or 4), unstable angina pectoris, uncontrolled cardiac arrhythmia or interstitial lung disease.
- Prisoners or subjects who are involuntarily incarcerated, or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness would be excluded.
- Prolonged QTcF interval >480 msec.
- Known hypersensitivity to cisplatin, gemcitabine or CPI-613, or its inactive components.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04203160
|United States, Arizona|
|University of Arizona Cancer Center||Recruiting|
|Tucson, Arizona, United States, 85724|
|Contact: Rachna Shroff, M.D. 520-626-4175 email@example.com|
|Principal Investigator: Rachna Shroff, M.D.|
|United States, Illinois|
|Northwestern University -- Lurie Comprehensive Cancer Center||Recruiting|
|Chicago, Illinois, United States, 60611|
|Contact: Lurie Cancer Center 312-695-1102 firstname.lastname@example.org|
|Principal Investigator: Devalingam Mahalingam, MBBChBAO|
|United States, Michigan|
|University of Michigan Rogel Cancer Center||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Cancer AnswerLine 800-865-1125 CancerAnswerLine@med.umich.edu|
|Principal Investigator: Vaibhav Sahai, MBBS, MS|
|United States, New Jersey|
|Atlantic Health System||Recruiting|
|Morristown, New Jersey, United States, 07960|
|Contact: Atlantic Hematology Oncology 973-971-7960 Angela.Alistar@atlantichealth.org|
|Contact: Angela Alistar, MD Angela.Alistar@atlantichealth.org|
|Principal Investigator: Angela Alistar, M.D.|
|United States, Ohio|
|University Hospitals - Seidman Cancer Center||Recruiting|
|Cleveland, Ohio, United States, 44106|
|Contact: UH Seidman CC 216-910-6304 david.bajor@UHhospitals.org|
|Principal Investigator: David Bajor, M.D.|
|United States, Pennsylvania|
|Allegheny Health Network||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15224|
|Contact: Nathan Bahary 412-864-7764 Nathan.Bahary@ahn.org|
|Principal Investigator: Nathan Bahary, MD, PhD|
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Laura Goff, M.D. 877-936-8422 email@example.com|
|Principal Investigator: Laura Goff, M.D.|
|United States, Texas|
|University of Texas Southwestern -- Simmons Comprehensive Cancer Center||Recruiting|
|Dallas, Texas, United States, 75390|
|Contact: David Hsiesh, M.D. 214-645-8300 Muhammad.Beg@UTSouthwestern.edu|
|Contact 214-648-1996 firstname.lastname@example.org|
|Principal Investigator: David Hsiesh, M.D.|
|United States, Washington|
|Fred Hutch/University of Washington Cancer Consortium||Recruiting|
|Seattle, Washington, United States, 98109|
|Contact: David Zhen, M.D. 206-606-1743 email@example.com|
|Principal Investigator: David Zhen, M.D.|
|United States, Wisconsin|
|University of Wisconsin - Carbone Cancer Center||Recruiting|
|Madison, Wisconsin, United States, 53705|
|Contact: Dustin Deming, M.D. 608-265-1042 firstname.lastname@example.org|
|Principal Investigator: Dustin Deming, M.D.|
|Principal Investigator:||Vaibhav Sahai, MBBS, MS||University of Michigan Rogel Cancer Center|
|Responsible Party:||University of Michigan Rogel Cancer Center|
|Other Study ID Numbers:||
HUM00170490 ( Other Identifier: University of Michigan )
|First Posted:||December 18, 2019 Key Record Dates|
|Last Update Posted:||December 22, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs